Takeda announces approval of cuvitru™ subcutaneous immunoglobulin in japan for patients with agammaglobulinemia or hypogammaglobulinemia

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the japanese ministry of health, labour and welfare has approved the use of cuvitru™ [immune globulin subcutaneous (human), 20% solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (pid) or secondary imm.
TAK Ratings Summary
TAK Quant Ranking